StockNews.AI
GMED
StockNews.AI
98 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc. – GMED

1. Pomerantz LLP investigates potential security fraud at Globus Medical, Inc. (GMED). 2. Globus reported Q1 2025 earnings missing estimates, causing a stock drop. 3. Stock fell 22.96% to $55.82 following disappointing financial results. 4. CEO cites supply chain disruptions and weaker deal closures as impact factors. 5. Investors encouraged to join a class action lawsuit for compensation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Globus's significant stock drop following earnings misses indicates strong negative sentiment. Past examples, like the post-earnings downturns in 2018, show sustained declines in similar scenarios.

How important is it?

The article signals severe financial distress and legal challenges for GMED, directly impacting investor confidence. The ongoing investigation can significantly affect stock performance and future forecasts.

Why Short Term?

Immediate investor sentiment and stock performance are impacted by current issues. If unresolved, legal actions may prolong negative sentiment in the short term, as seen with similar companies facing investigations.

Related Companies

MDTSYKHOLX
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, Globus issued a press release reporting its financial results for the first quarter of 2025. Among other items, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, missing consensus estimates by $27.78 million and representing a 1.4% year-over-year decline. Globus’s President and Chief Executive Officer said that the Company’s “first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders[.]”  On this news, Globus’s stock price fell $16.64 per share, or 22.96%, to close at $55.82 per share on May 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News